These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 2870907)

  • 21. Regioselective and stereoselective metabolisms of pyrene and 1-bromopyrene by rat liver microsomes and effects of enzyme inducers.
    Shou M; Yang SK
    Drug Metab Dispos; 1988; 16(2):173-83. PubMed ID: 2898329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. S-oxidation of thiobenzamide by rat liver microsomes.
    Chieli E; Malvaldi G; Poggi G; Giusiani M; Palagi U
    Boll Soc Ital Biol Sper; 1981 Jul; 57(13):1457-62. PubMed ID: 7284113
    [No Abstract]   [Full Text] [Related]  

  • 23. o-Hydroxyphenylethanol, a novel lactone ring-opened metabolite of coumarin.
    Norman RL; Wood AW
    Drug Metab Dispos; 1984; 12(5):543-9. PubMed ID: 6209076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance.
    Prakash C; Wang W; O'Connell T; Johnson KA
    Drug Metab Dispos; 2008 Oct; 36(10):2093-103. PubMed ID: 18653741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans.
    Lang D; Freudenberger C; Weinz C
    Drug Metab Dispos; 2009 May; 37(5):1046-55. PubMed ID: 19196846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolism of 6-methylbenz[a]anthracene by rat liver microsomes and mutagenicity of metabolites.
    Mushtaq M; Fu PP; Miller DW; Yang SK
    Cancer Res; 1985 Sep; 45(9):4006-14. PubMed ID: 3896475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolism of olaquindox in rat liver microsomes: structural elucidation of metabolites by high-performance liquid chromatography combined with ion trap/time-of-flight mass spectrometry.
    Liu Z; Huang L; Dai M; Chen D; Wang Y; Tao Y; Yuan Z
    Rapid Commun Mass Spectrom; 2008 Apr; 22(7):1009-16. PubMed ID: 18320546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolation, identification and immunosuppressive activity of a new IMM-125 metabolite from human liver microsomes. Identification of its cyclophilin A-IMM-125 metabolite complex by nanospray tandem mass spectrometry.
    Lhoëst GJ; de Jong AP; Meiring HD; Maton N; Latinne D; Verbeeck RK; Otte JB; Zurini M
    J Mass Spectrom; 1998 Oct; 33(10):936-42. PubMed ID: 9821326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The yin and yang of lidocaine and cyclosporine metabolism in liver graft recipients.
    Christians U; Kohlhaw K; Esselmann H; Sürig T; Luy M; Kaltefleiter M; Beyrau R; Linck A; Ringe B; Oellerich M
    Transplant Proc; 1994 Oct; 26(5):2827-8. PubMed ID: 7940891
    [No Abstract]   [Full Text] [Related]  

  • 30. Extraction and metabolism of lidocaine in rat liver.
    Nyberg G; Karlén B; Hedlund I; Grundin R; von Bahr C
    Acta Pharmacol Toxicol (Copenh); 1977 Feb; 40(2):337-46. PubMed ID: 576562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age associated alteration of lidocaine metabolism is position selective.
    Fujita S; Tatsuno J; Kawai R; Kitagawa H; Suzuki T; Kitani K
    Biochem Biophys Res Commun; 1985 Jan; 126(1):117-22. PubMed ID: 3970687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of cyclosporine-A pretreatment on lidocaine metabolite formation in the regenerating rat liver.
    Pietrabissa A; Di Stefano R; Collecchi P; Campanella PG; Della Capanna S; Scarcello E; Turini L; Bevilacqua G; Mosca F
    Transplant Proc; 1994 Oct; 26(5):2908-9. PubMed ID: 7940918
    [No Abstract]   [Full Text] [Related]  

  • 33. [High-performance liquid chromatographic method for plasma or serum level monitoring of lidocaine and its active metabolites].
    Saegusa Y; Watanabe M; Ohno H; Hasegawa Y; Kawamoto T; Hanawa K
    Rinsho Byori; 1986 Oct; 34(10):1193-7. PubMed ID: 3543441
    [No Abstract]   [Full Text] [Related]  

  • 34. The effects of gonadectomy and hypophysectomy on the metabolism of imipramine and lidocaine by the liver of male and female rats.
    Skett P; Mode A; Rafter J; Sahlin L; Gustafsson JA
    Biochem Pharmacol; 1980 Oct; 29(20):2759-62. PubMed ID: 7437081
    [No Abstract]   [Full Text] [Related]  

  • 35. Reactive metabolite screen for reducing candidate attrition in drug discovery.
    Chen WG; Zhang C; Avery MJ; Fouda HG
    Adv Exp Med Biol; 2001; 500():521-4. PubMed ID: 11764991
    [No Abstract]   [Full Text] [Related]  

  • 36. Identification of glycinexylidide in patients treated with intravenous lidocaine.
    Strong JM; Parker M; Atkinson AJ
    Clin Pharmacol Ther; 1973; 14(1):67-72. PubMed ID: 4683073
    [No Abstract]   [Full Text] [Related]  

  • 37. Biotransformation of lidocaine.
    Difazio CA
    Int Anesthesiol Clin; 1975; 13(4):21-32. PubMed ID: 1205644
    [No Abstract]   [Full Text] [Related]  

  • 38. A new lidocaine metabolite, omega-diethylamino-2-hydroxymethyl-6-methylacetanilide.
    Kawai R; Fujita S; Suzuki T
    Drug Metab Dispos; 1986; 14(2):277-9. PubMed ID: 2870907
    [No Abstract]   [Full Text] [Related]  

  • 39. In-vitro metabolism of lignocaine to its N-oxide.
    Patterson LH; Hall G; Nijjar BS; Khatra PK; Cowan DA
    J Pharm Pharmacol; 1986 Apr; 38(4):326. PubMed ID: 2872305
    [No Abstract]   [Full Text] [Related]  

  • 40. Extraction of omega- and omega-1-hydroxylauric acids with ethyl acetate results in formation of acetoxy products.
    Salhab AS; Applewhite J; Couch MW; Okita RT; Shiverick KT
    Drug Metab Dispos; 1987; 15(2):233-6. PubMed ID: 2882984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.